1446507-38-5

Basic information

• Product Name: 6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazine-2,4(1H,3H)-dione
• Synonyms: 6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazine-2,4(1H,3H)-dione;Enasidenib Intermediate 2
• CAS NO: 1446507-38-5
• Molecular Formula: C₉H₅F₃N₄O₂
• Molecular Weight: 258.1568096
• EINECS: -0
• Mol File: 1446507-38-5.mol
• Article Data: 23

Chemical Properties

• Appearance: /
• Density: 1.74±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 4.09±0.70(Predicted)
• CAS DataBase Reference: 6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazine-2,4(1H,3H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazine-2,4(1H,3H)-dione(1446507-38-5)
• EPA Substance Registry System: 6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazine-2,4(1H,3H)-dione(1446507-38-5)

Safety Data

• Hazardous Substances Data: 1446507-38-5(Hazardous Substances Data)

Usage

General Description

6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazine-2,4(1H,3H)-dione is a chemical compound with a molecular formula of C11H6F3N5O2. It is a derivative of 1,3,5-triazine and contains a trifluoromethylpyridinyl group. 6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazine-2,4(1H,3H)-dione is commonly used in the field of medicinal chemistry and pharmaceutical research, due to its potential for developing new drugs and treatments. It may have biological activity and is being investigated for its potential uses in various therapeutic applications. Additionally, it may also be utilized in organic synthesis and as a building block in the production of other chemical compounds.

Upstream product

• 39890-95-4 2-chloro-6-trifluoromethylpyridine 
• 108-19-0 BIURET 
• 155377-05-2 6-(trifluoromethyl)pyridine-2-carboxylic acid methyl ester 
• 887583-52-0 6-(trifluoromethyl)pyridine-2-carbonitrile 
• 189278-27-1 2-bromo-6-(trifluoromethyl)pyridine 
• 131747-42-7 6-(trifluoromethyl)pyridine-2-carboxylic acid 
• 368-48-9 2-(trifluoromethyl)pyridine 

Downstream Products

• 1446507-40-9 2,4-dichloro-6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazine 
• 1446502-11-9 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol 
• 1446507-68-1 4-chloro-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoro-methyl)-pyridin-4-yl)-1,3,5-triazin-2-amine 

Relevant articles and documents

Compound with IDH mutant inhibitory activity, preparation method and application thereof

The invention belongs to the field of medicines, and particularly relates to a s-triazine compound with structural characteristics of a general formula I or a pharmaceutically acceptable salt thereof,a pharmaceutical composition and a preparation method thereof, and application of the s-triazine compound or the pharmaceutically acceptable salt and the pharmaceutical composition in preparation ofIDH2 mutant inhibitors. According to the invention, pharmacological experiment results show that the compound disclosed by the invention has an obvious inhibition effect on the activity of an IDH2 mutant (mIDH2), can effectively inhibit the process that alpha-ketoglutaric acid is catalyzed by mIDH2 to generate 2-hydroxyglutaric acid, and can be used for preparing drugs for preventing and/or treating various related diseases caused by IDH2 mutation, wherein the diseases comprise cancers carrying IDH2 mutation.

Structure-based design, synthesis and bioactivity evaluation of macrocyclic inhibitors of mutant isocitrate dehydrogenase 2 (IDH2) displaying activity in acute myeloid leukemia cells

The enzymes involved in the metabolic pathways in cancer cells have been demonstrated as important therapeutic targets such as the isocitrate dehydrogenase 2 (IDH2). A series of macrocyclic derivatives was designed based on the marketed IDH2 inhibitor AG-221 by using the conformational restriction strategy. The resulted compounds showed moderate to good inhibitory potential against different IDH2-mutant enzymes. Amongst, compound C6 exhibited better IDH2R140Q inhibitory potency than AG-221, and showed excellent activity of 2-hydroxyglutarate (2-HG) suppression in vitro and its mesylate displayed good pharmacokinetic profiles. Moreover, C6 performed strong binding mode to IDH2R140Q after computational docking and dynamic simulation, which may serve as a good starting point for further development.

Substituted triazine-based IDH inhibitor optical isomers and applications thereof

The present invention belongs to the field of medical chemistry, and relates to a class of substituted triazine-based IDH inhibitor optical isomers and applications thereof, and specifically providesoptical isomers represented by a formula I or formula II or hydrates, solvates, crystals or pharmaceutically acceptable salts thereof, and a preparation method thereof, a pharmaceutical composition containing the optical isomers or hydrates, solvates, crystals or pharmaceutically acceptable salts thereof, and uses in treatment of cancer characterized by the presence of mutant isocitrate dehydrogenase 2. According to the present invention, the compounds have good inhibitory activity against IDH2, and can be used as the cancer treatment agents with advantages of high treatment effect and low side effect. The formulas I and II are defined in the specification.